(S)-2,6-Diamino-hexanoic acid methylamide | 66760-51-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-2,6-Diamino-hexanoic acid methylamide
• 英文别名: (S)-2,6-Diamino-N-methylhexanamide；(2S)-2,6-diamino-N-methylhexanamide
• CAS: 66760-51-8
• 化学式: C₇H₁₇N₃O
• 分子量: 159.231
• InChiKey: PZVHMLQLXAUQGY-LURJTMIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.2
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  81.1
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-2,6-Diamino-hexanoic acid methylamide 在 palladium on activated charcoal lithium hydroxide 、 二氯特诺 、 氢气 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 生成 (2R,3R)-N⁴-((S)-5-Amino-1-methylcarbamoyl-pentyl)-2,N¹-dihydroxy-2-methyl-3-(3-phenyl-propyl)-succinamide
  参考文献：
  名称：

  Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases

  摘要：

  Examination of the S1 area of the active site of pro-stromelysin has led us to the design of novel and potent inhibitors of matrix metalloproteinases containing constrained quaternary-hydroxy group at pi. The synthesis and biological activity of these compounds with variations at P1', P2', and P3' will be described. (C) 1998 The DuPont Merck Pharmaceutical Company. Published by Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00125-5
• 作为产物：
  描述：

  L-赖氨酸 、 甲胺 在 氯化亚砜 作用下， 生成 (S)-2,6-Diamino-hexanoic acid methylamide
  参考文献：
  名称：

  Pavlik, Manfred; Kluh, Ivan; Pavlikova, Frantiska, Collection of Czechoslovak Chemical Communications, 1989, vol. 54, # 7, p. 1940 - 1954

  摘要：

  DOI：

文献信息

• [EN] FURAZANOBENZIMIDAZOLES AS PRODRUGS TO TREAT NEOPLASTIC OR AUTOIMMUNE DISEASES<br/>[FR] FURAZANOBENZIMIDAZOLES EN TANT QUE PRÉCURSEURS DESTINÉS AU TRAITEMENT DE MALADIES NÉOPLASIQUES OU AUTO-IMMUNES
  申请人：BASILEA PHARMACEUTICA AG

  公开号：WO2011012577A1

  公开（公告）日：2011-02-03

  A compound of formula (II) wherein (a) represents a divalent benzene residue which is unsubstituted or substituted by one or two additional substituents independently selected from lower alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower alkoxy-lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino, mono(lower alkyl)amino, di(lower alkyl)amino, mono(lower alkenyl)amino, di(lower alkenyl)amino, lower alkoxycarbonylamino, lower alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form together with the nitrogen heterocyclyl, lower alkylcarbonyl, carboxy, lower 15 alkoxycarbonyl, cyano, halogen, and nitro; or wherein two adjacent substituents can be methylenedioxy; or a divalent pyridine residue (Z = N) which is unsubstituted or substituted additionally by lower alkyl, lower alkoxy, lower alkoxy-lower alkoxy,amino, optionally substituted by one or two substituents selected from lower alkyl, lower alkenyl and alkylcarbonyl, halo-20 lower alkyl, lower alkoxy-lower alkyl, or halogen; R1 represents hydrogen, lower alkylcarbonyl, hydroxy-lower alkylor cyano-loweralkyl; and R2 represents a group selected from: (b), (c) and (d); or pharmaceutically acceptable salts thereof.

  式（II）的化合物，其中（a）代表一个二价苯残基，该残基未取代或被一个或两个额外取代基独立选择自较低烷基、卤代较低烷基、羟基较低烷基、较低烷氧基较低烷基、酰氧较低烷基、苯基、羟基、较低烷氧基、羟基较低烷氧基、较低烷氧基较低烷氧基、苯基较低烷氧基、较低烷基羰基氧基、氨基、单（较低烷基）氨基、二（较低烷基）氨基、单（较低烯基）氨基、二（较低烯基）氨基、较低烷氧羰基氨基、较低烷基羰基氨基、取代氨基，其中氮上的两个取代基与氮一起形成杂环基、较低烷基羰基、羧基、较低烷氧羰基、氰基、卤素和硝基；或其中两个相邻的取代基可以是亚甲二氧基；或一个未取代或另外被较低烷基、较低烷氧基、较低烷氧基较低烷氧基、氨基、可选择地被较低烷基、较低烯基和烷基羰基、卤代较低烷基、较低烷氧基较低烷基或卤素中的一个或两个取代基取代的二价吡啶残基（Z = N）；R1代表氢、较低烷基羰基、羟基较低烷基或氰基较低烷基；R2代表从中选择的一组：（b）、（c）和（d）；或其药学上可接受的盐。
• [EN] TARGETED CONTRAST AGENTS COMPRISING A HYDRAZIDE FUNCTIONAL GROUP<br/>[FR] AGENTS DE CONTRASTE CIBLÉ COMPRENANT UN GROUPE FONCTIONNEL D'HYDRAZIDE
  申请人：RF THERAPEUTICS INC

  公开号：WO2016090491A1

  公开（公告）日：2016-06-16

  Described herein is a contrast agent for administration to a subject. The contrast agent includes a targeting portion that includes a hydrazide functional group; a metal ion bound to a metal-complexable portion; and a linker joining the targeting portion and the metal- complexable portion of the contrast agent. The portion that is not bound to a metal ion localizes the contrast agent to necrotic tissue in the subject.

  本文描述了一种用于给予受试者的对比剂。该对比剂包括一个包含肼基官能团的靶向部分；与可形成金属络合物的部分结合的金属离子；以及连接靶向部分和金属络合物部分的对比剂的连接剂。未结合金属离子的部分将对比剂定位到受试者的坏死组织中。
• [EN] TETRAHYDROTHIOPHENE-BASED GABA AMINOTRANSFERASE INACTIVATORS<br/>[FR] INACTIVATEURS DE LA GABA AMINOTRANSFÉRASE À BASE DE TÉTRAHYDROTHIOPHÈNE
  申请人：UNIV NORTHWESTERN

  公开号：WO2016145082A1

  公开（公告）日：2016-09-15

  Tetrahydrothiophene and related heterocyclic analogs and related methods for GABA aminotransferase inactivation.

  硫代四氢噻吩及其相关杂环类似物以及相关的GABA氨基转移酶失活方法。
• Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them
  申请人：——

  公开号：US20040053911A1

  公开（公告）日：2004-03-18

  Metal-complexable substituted bis-indole derivatives comprising the structure shown in formula (I) hereunder: enantiomers and pharmaceutically acceptable salts thereof and metal complexes thereof, wherein L, R 1 , R 2 , R 3 , C 1 , C 2 , m, n, p, q and r are as defined in claim 1 for use as constrats agents.

  具有以下式子（I）所示结构的金属络合取代双吲哚衍生物：其对映体、药学上可接受的盐及其金属络合物，其中L、R1、R2、R3、C1、C2、m、n、p、q和r如权利要求1所定义，用作造影剂。
• Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels
  申请人：Rau Harald

  公开号：US20120156259A1

  公开（公告）日：2012-06-21

  The present invention relates to biodegradable polyethylene glycol based water-insoluble hydrogels comprising backbone moieties which are interconnected by hydrolytically degradable bonds, the backbone moieties further comprising reactive functional groups, wherein the water-insoluble hydrogel is further characterized in that the ratio between the time period for the complete degradation of the hydrogel by hydrolysis of the degradable bonds into water-soluble degradation products comprising one or more backbone moieties and the time period for the release of the first 10 mol-% of water-soluble degradation products comprising one or more backbone moieties based on the total amount of backbone moieties in the hydrogel is greater than 1 and equal to or less than 2. The invention further relates to conjugates of such hydrogels with ligands or ligating groups, prodrugs and pharmaceutical compositions as well as their use in a medicament.

  本发明涉及可生物降解的聚乙二醇基水不溶性水凝胶，其包含通过水解降解键相互连接的骨架基团，骨架基团进一步包括反应性功能团，其中水不溶性水凝胶的特征在于，通过水解降解可将可降解键分解为可溶于水的降解产物，包括一个或多个骨架基团，完全降解水凝胶所需的时间与基于水凝胶中所有骨架基团数量的第一个10摩尔％可溶性降解产物的释放时间之比大于1且小于等于2。本发明还涉及这种水凝胶与配体或配位基团的共轭物、前药和制药组合物以及它们在药物中的使用。